Frontier Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$63.1M Sell
564,133
-176,733
-24% -$20.2M 0.67% 41
2026
Q2
$85M Sell
740,866
-18,982
-2% -$1.63M 0.79% 27
2026
Q1
$63.3M Buy
759,848
+123,891
+19% +$9.8M 0.65% 38
2025
Q4
$49.5M Buy
635,957
+117,900
+23% +$7.96M 0.53% 56
2025
Q3
$29.3M Buy
518,057
+26,247
+5% +$1.18M 0.26% 140
2025
Q2
$21.5M Buy
491,810
+359,847
+273% +$12.4M 0.2% 178
2025
Q1
$3.61M Sell
131,963
-18,209
-12% -$664K 0.04% 264
2024
Q4
$6.04M Sell
150,172
-242,091
-62% -$10.9M 0.06% 249
2024
Q3
$18.6M Buy
+392,263
New +$17.3M 0.17% 175

Other funds holding KYMR

Frontier Capital Management's KYMR Position: Q3 2026 in Review

Frontier Capital Management reduced its Kymera Therapeutics (KYMR) stake by 24% in Q3 2026, selling an estimated $20.2M and leaving 564,133 shares worth $63.1M. The position accounts for 0.67% of the portfolio, ranked #41.

Frontier Capital Management first reported a position in KYMR in Q3 2024 and has held it in 9 quarters since. The position peaked at $85M in Q2 2026. 301 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • Frontier Capital Management held 564,133 shares of Kymera Therapeutics worth $63.1M as of Q3 2026.
  • Frontier Capital Management sold 176,733 Kymera Therapeutics shares in Q3 2026, an estimated $20.2M.
  • Kymera Therapeutics made up 0.67% of Frontier Capital Management's portfolio in Q3 2026, its #41 holding.
  • Frontier Capital Management first reported a position in Kymera Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • Frontier Capital Management's Kymera Therapeutics position peaked at $85M in Q2 2026.
  • 301 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Frontier Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.